These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8588064)

  • 1. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
    Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
    Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
    Rouillard C; Bédard PJ; Di Paolo T
    Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
    Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
    Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
    J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
    Calon F; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Neurochem Int; 1999 Jul; 35(1):81-91. PubMed ID: 10403433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
    Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
    Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
    Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists.
    Gagnon C; Bédard PJ; Di Paolo T
    Eur J Pharmacol; 1990 Mar; 178(1):115-20. PubMed ID: 1970537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N; Mizuta E; Yoshida O; Kuno S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
    Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
    Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys.
    Luquin MR; Guillén J; Legarda I; Cruz Rodriguez M; Del Rio L; Dominguez J; Martínez-Lage JM
    Adv Neurol; 1996; 69():239-44. PubMed ID: 8615134
    [No Abstract]   [Full Text] [Related]  

  • 14. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
    Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
    Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
    Calon F; Morissette M; Ghribi O; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):127-38. PubMed ID: 11853103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
    Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM
    Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.
    Goulet M; Morissette M; Calon F; Blanchet PJ; Falardeau P; Bédard PJ; Di Paolo T
    Neuroscience; 1997 Jul; 79(2):497-507. PubMed ID: 9200732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.